About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
PMID: 35583667 Journal: NEURORADIOLOGY Year: 2022 Reference: Neuroradiology. 2022 May 18. pii: 10.1007/s00234-022-02973-2. doi: 10.1007/s00234-022-02973-2. Impact factor: 2.804 Publication type: Paper in international publication Authors: Aymerich, Francesc Xavier, Auger, Cristina, Alonso, Julio, Barros, Andrea, Clarke, Margareta A, Mora, Juan, Arrambide, Georgina, Corral, Juan Francisco, Andrino, Ana, Sastre-Garriga, Jaume et al. DOI: 10.1007/s00234-022-02973-2
PMID: 35580993 Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Year: 2022 Reference: J Neurol Neurosurg Psychiatry. 2022 Jul;93(7):741-752. doi: 10.1136/jnnp-2022-328908. Epub 2022 May 17. Impact factor: 10.283 Publication type: Paper in international publication Authors: Margoni, Monica, Pagani, Elisabetta, Meani, Alessandro, Storelli, Loredana, Mesaros, Sarlota, Drulovic, Jelena, Barkhof, Frederik, Vrenken, Hugo, Gallo, Antonio, Bisecco, Alvino et al. DOI: 10.1136/jnnp-2022-328908
PMID: 35549532 Journal: Multiple Sclerosis Journal Year: 2022 Reference: Mult Scler. 2022 Jun;28(7):1005-1008. doi: 10.1177/13524585221099844. Epub 2022 May 13. Impact factor: 6.312 Publication type: Editorail in international publication Authors: Thompson, Alan J, Montalban, Xavier, Zabalza, Ana et al. DOI: 10.1177/13524585221099844
PMID: 35538884 Journal: Clinical and Translational Medicine Year: 2022 Reference: Clin Transl Med. 2022 May;12(5):e837. doi: 10.1002/ctm2.837. Impact factor: 11.492 Publication type: Letter whit IF Authors: Matute-Blanch, Clara, Brito, Veronica, Midaglia, Luciana, Villar, Luisa M, Garcia-Diaz Barriga, Gerardo, Guzman de la Fuente, Alerie, Borras, Eva, Fernandez-Garcia, Sara, Calvo-Barreiro, Laura, Miguez, Andres et al. DOI: 10.1002/ctm2.837
PMID: 32390548 Journal: STROKE Year: 2020 Reference: Stroke. 2020 Jun;51(6):1766-1771. doi: 10.1161/STROKEAHA.119.028586. Epub 2020 May 11. Impact factor: 7.19 Publication type: Paper in international publication Authors: Rubiera, Marta, Molina, Carlos A, Tomasello, Alejandro, Ribo, Marc, Hernandez, David, Rodriguez-Luna, David, Pagola, Jorge, Coscojuela, Pilar, Requena, Manuel, Olive, Marta et al. DOI: 10.1161/STROKEAHA.119.028586
PMID: 32390131 Journal: REVISTA DE NEUROLOGIA Year: 2020 Reference: Rev Neurol. 2020 May 16;70(10):379-390. doi: 10.33588/rn.7010.2020121. Impact factor: 0.562 Publication type: Review in national publication Authors: Prieto, J M, Fernandez, O, Aladro, Y, Arroyo, R, Brieva, Ll, Calles-Hernandez, M C, Carrascal, P, Comabella, M, Costa-Frossard, L, Eichau, S et al. DOI: 10.33588/rn.7010.2020121
PMID: 30887862 Journal: Multiple Sclerosis Journal Year: 2020 Reference: Mult Scler. 2020 Apr;26(4):476-488. doi: 10.1177/1352458519837707. Epub 2019 Mar 19. Impact factor: 5.412 Publication type: Paper in international publication Authors: Koini, Marisa, d'Ambrosio, Alessandro, Valsasina, Paola, Gallo, Antonio, De Stefano, Nicola, Pareto, Deborah, Barkhof, Frederik, Ciccarelli, Olga, Enzinger, Christian, Tedeschi, Gioacchino et al. DOI: 10.1177/1352458519837707
PMID: 32246177 Journal: NEURORADIOLOGY Year: 2020 Reference: Neuroradiology. 2020 Aug;62(8):955-964. doi: 10.1007/s00234-020-02401-3. Epub 2020 Apr 3. Impact factor: 2.238 Publication type: Paper in international publication Authors: Cappelle, Sarah, Pareto, Deborah, Tintore, Mar, Alyafeai, Rumaiza, Vidal-Jordana, Angela, Alberich, Manel, Sastre-Garriga, Jaume, Auger, Cristina, Montalban, Xavier, Rovira, Alex et al. DOI: 10.1007/s00234-020-02401-3
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
